Omnicell (NASDAQ:OMCL) Releases Q2 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its second quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.190-0.320 for the period, compared to the consensus earnings per share estimate of 0.420. The company issued revenue guidance of $270.0 million-$280.0 million, compared to the consensus revenue estimate of $278.1 million.

Analyst Ratings Changes

OMCL has been the subject of several research analyst reports. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company reduced their price target on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Benchmark reaffirmed a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. JPMorgan Chase & Co. decreased their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Finally, Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $50.67.

Omnicell Trading Down 14.6 %

Shares of Omnicell stock traded down $4.44 on Tuesday, hitting $26.05. 889,718 shares of the company’s stock traded hands, compared to its average volume of 538,017. Omnicell has a one year low of $23.31 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a market capitalization of $1.22 billion, a PE ratio of 96.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The firm’s 50-day moving average price is $33.28 and its two-hundred day moving average price is $40.38.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts expect that Omnicell will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.